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On a global scale, asthma is the most common chronic non-communi-
cable disease in children. It is a heterogeneous condition characterised by 
chronic inflammation and variable expiratory airflow limitation,[1] as well 
as airway reversibility (evidence level C). Airway inflammation and airway 
obstruction are features of asthma and are usually not measured in young 
children, except in research settings. The term asthma, therefore, should 
not be used to describe preschool wheezing illness.[2] The child should 
demonstrate clinical improvement during 2 - 3 months of controller treat-
ment, with worsening of symptoms after treatment cessation.[3] A history 
of other allergic disease (eczema or allergic rhinitis) or asthma in first-
degree relatives is useful in some instances (evidence level B). 
Objectives
We reviewed the current literature on the diagnosis of asthma 
in children, with particular emphasis on young children and the 
available evidence. We also examined the assessment of asthma 
control in children and the current evidence basis for the importance 
of these assessments.
Methods
The South African Childhood Asthma Working Group (SACAWG) 
convened in January 2017 with six task groups, each assigned 
to a section leader (Appendix A), who constituted the editorial 
committee on assessment of asthma epidemiology, diagnosis, 
control, treatments, novel treatments and self-management plans. 
The task groups reviewed the available scientific literature on the 
diagnosis of asthma and assessment of asthma control in young 
children according to high-quality evidence, graded the level of 
evidence, and made recommendations based on the literature 
(Appendix B). 
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Background. Asthma is a heterogeneous condition characterised by chronic inflammation and variable expiratory airflow limitation, as 
well as airway reversibility. The diagnosis of asthma in young children is limited by the inability to perform objective lung function testing 
in this group of patients and the wide variety of conditions that can phenotypically present with asthma-like symptoms.
Objectives. To provide an evidence-based approach for clinicians to accurately diagnose asthma in young children and to assess the level 
of control to guide therapeutic decisions.
Methods. The South African Childhood Asthma Working Group (SACAWG) convened in January 2017 with task groups, each headed by a 
section leader, constituting the editorial committee on assessment of asthma epidemiology, diagnosis, control, treatments, novel treatments 
and self-management plans. The asthma diagnosis and control task groups reviewed the available scientific literature and assigned evidence 
according to the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system, providing recommendations 
based on current evidence.
Conclusions. Asthma in young children should only be diagnosed if all other causes of wheezing have been considered and excluded, and 
if there is a response to a therapeutic trial and worsening with withdrawal of asthma medication. Asthma control should be assessed at each 
visit to guide therapeutic decisions.
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Asthma in children
The presentation and differential diagnosis of asthma differ 
significantly as the child matures. For the purpose of this review 
and in line with the current literature, children are categorised as 
preschoolers (<5 years of age) and older children.
Children <5 years of age
One-third of all children wheeze at least once before their third 
birthday. Children <5 years old are prone to frequently recurring 
viral upper-respiratory tract infections, which may be associated 
with wheeze. Although wheeze commonly occurs, most children are 
asymptomatic by school-going age, with only one-quarter having 
persistent symptoms and later developing asthma[2] (evidence level B). 
In South Africa (SA), wheeze and asthma need to be distinguished 
from other causes of pneumonia, e.g. tuberculosis and other bacterial 
pneumonias (Table 1). 
Predictive indices for asthma
As asthma in infancy and preschoolers has nonspecific symptoms, 
making it difficult to determine who has or will have asthma, 
predictive models have been developed.[4] These models have been 
proposed to improve early diagnosis, and therefore early access to 
treatment.[5] Some of the predictive models are the modified asthma 
predictive index (mAPI) and the prevention and incidence of asthma 
and mite allergy (PIAMA) risk score (evidence level C).[5,6] Use of 
these scores has not been validated in the African setting, where the 
atopy levels are lower (evidence level C), and should therefore not be 
used in the SA context.
History
History-taking alone is often all that is needed to diagnose a 
preschool wheezing disorder. Rather than categorising the wheezy 
‘phenotype’ of the child, the decision to initiate an asthma therapeutic 
trial should primarily be determined by the following: 
• Severity of wheezy episodes (presence of dyspnoea, increased 
respiratory rate and need for oxygen therapy during the  episode).
• Frequency of wheezy episodes (the child is symptomatic for 
>10 days during upper-respiratory tract infections or has >3 wheezy 
episodes per year). 
• Temporal pattern of symptoms (presence of wheezing not only 
with viral colds (infections), but triggered by allergens, irritants 
(pollution), exercise and sudden emotional changes (crying or 
laughing) between episodes (evidence level C) or worsening of 
symptoms on most days and nights). 
• Reversibility of wheezy episodes (bronchodilator response test 
(evidence level D)).
• A positive family history of eczema (allergic dermatitis), allergic 
rhinitis, allergic conjunctivitis and/or food allergy (evidence level B).
• History of an individual child’s allergic problems, as mentioned 
above.
Clinical examination
This may be unhelpful in the young child, especially where there are 
no other atopic manifestations, but it must be remembered that ‘not 
all that wheezes is asthma’. 
Therapeutic trial
The current evidence based on symptoms and their relationship 
to asthma diagnosis in under-5 children are set out in Table 2. 
The principle when starting treatment for a child with a wheezing 
disorder is that treatment should be viewed as a therapeutic trial, 
i.e. therapy should be initiated and the child followed up after 6 - 8 
weeks (Fig. 1).[1,7,8] If there is no clinical response to therapy, it 
should be discontinued and a differential diagnosis considered as 
the cause of wheezing (Table 1). Should the child respond to therapy 
after the trial, medication should be discontinued. The reasons for a 
therapeutic response may be owing to the child being asthmatic or 
the natural history of improvement in the case of viral infections. 
Should symptoms recur after withdrawal of therapy, the child can be 
placed on maintenance therapy.[7,8]
Early use of inhaled corticosteroids (ICSs) in preschool children 
with wheeze, reduces symptoms and prevents or delays the onset of 
Table 1. Differential diagnosis of wheeze in children <5 years of age*
Category Disease entity
Congenital upper airway Complete tracheal rings
Tracheomalacia 
Laryngomalacia
Vocal cord palsy/paresis
Subglottic stenosis/post-intubation/ congenital
Congenital lower airway Vascular rings/slings
Bronchomalacia
Aspiration Gastroesophageal reflux disease 
Swallowing inco-ordination
Laryngeal cleft
Tracheo-oesophageal fistula
Bronchiectasis Cystic fibrosis
Primary ciliary dyskinesia
Persistent bacterial bronchitis 
Primary immunodeficiency 
HIV
Endobronchial lesions Foreign body
Tuberculosis granuloma
Malignancies
Cardiac Enlarged heart
Congenital heart disease (left-to-right shunts)
*Adapted from White et al.[3]
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asthma in children (evidence level A).[9-11] Therefore, early institution 
of therapy will not improve lung function of those who do not have 
asthma. 
There are specific clinical pointers, which should guide the 
healthcare practitioner to seek another diagnosis in children with 
persistent wheezing (Box 1).
Children 6 - 11 years of age
For children ≥6 years of age, besides the presenting symptoms, 
variable airflow limitation can be demonstrated by objective testing 
on peak flow measurements or by spirometry (Box 2) – ideally before 
commencement of controller medication. Normal lung function 
tests do not exclude the diagnosis of asthma (evidence level B).[12] 
Where the history is suggestive of asthma with normal spirometry, 
other specialised tests, such as methacholine challenge and exercise 
challenge tests, may be done by a pulmonologist to confirm the 
diagnosis (Appendix C). 
If the respiratory symptoms are suggestive of asthma, but 
not confirmed by variable airflow limitation or resolution with 
commencement of therapy, an alternative diagnosis is usually sought 
and may include those listed in Table 3. Some of these conditions may 
coexist with asthma. Investigations that are not helpful in diagnosing 
asthma include chest radiography, which may be normal or show 
evidence of air trapping with hyperinflation.
 Restart chronic 
asthma treatment 
and review 
3 - 4-monthly
Therapeutic trial
6 - 8 weeks
STOP
No change                             Worsening
Stop asthma
therapy
Fig. 1. Therapeutic trial and review protocol for young children with suspected 
asthma.
Table 2. Diagnostic characteristics of asthma in children <5 years of age and grade of recommendation* 
Characteristics Grade
Exercise-/activity-induced symptoms
Nocturnal coughing (problematic, with awakening)
Symptoms persisting in children >3 years old
A
Response to a bronchodilator (short-acting beta-agonist)
No seasonal variation in symptoms
Viral colds with accompanying chest involvement
Symptoms with specific trigger exposure, including emotional upsets (e.g. crying and laughing)
Response to a short course of oral corticosteroids during acute exacerbation of symptoms
Comorbid allergic rhinitis, proven food allergy and atopic dermatitis
Absence of seasonal variation
B
Wheezing lasting >1 month C
A positive modified bronchodilator test D
*Adapted from Global Initiative for Asthma.[1]
Table 3. Differential diagnosis of asthma in children 6 - 11 years of age*                           
Condition Symptoms
Chronic upper-airway cough syndrome Sneezing, itching, blocked nose, throat clearing
Inhaled foreign body Sudden onset of symptoms, unilateral wheeze
Bronchiectasis Recurrent infections, productive cough
Primary ciliary dyskinesia Recurrent infections, productive cough, sinusitis
Congenital heart disease Cardiac murmurs
Bronchopulmonary dysplasia Preterm delivery, symptoms since birth
Cystic fibrosis Excessive cough and mucus production, gastrointestinal symptoms
*Adapted from Global Initiative for Asthma.[1]
Box 1. Clinical signs in children <5 years of age, suggesting an 
alternative diagnosis and a need for specialist referral 
Failure to thrive
Continuous wheezing without a clear history of exacerbation
Digital clubbing
Failure to respond to 2 - 3 months’ optimal asthma treatment 
(e.g. correct technique, compliance)
Vomiting associated with respiratory symptoms
Very young age of onset of respiratory symptoms (often during the 
first month of life)
Severe hypoxaemia at clinical presentation
Focal/segmental lung signs
Cardiovascular signs
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Table 4. Assessment of asthma control and future risk in children <5 years of age (evidence level B)*
Symptom control Well controlled Partly controlled Uncontrolled
In the past week, has the patient had:
• Daytime asthma symptoms more than twice per week
• Any night-time awakening due to asthma
• Reliever use more than twice per week
• Limitation of activity
None 1 - 2 3 - 4 
Risk factors for poor asthma outcomes
Assess the patient’s risk for
Exacerbations
Uncontrolled asthma symptoms
One or more exacerbations in the previous year
Start of the child’s usual ‘flare-up’ season (especially if autumn)
 Exposures: tobacco smoke, indoor or outdoor air pollution, indoor allergens (e.g. house-dust mite, cockroaches, pets, mould), 
especially in combination with viral infection
Major psychological or socioeconomic problems for child or family
Poor adherence with controller medication or incorrect inhaler technique
Fixed airflow obstruction
Severe asthma with several hospitalisations
History of bronchiolitis
Medication side-effects
Systemic: frequent courses of OCSs, high-dose and/or potent ICSs
 Local: moderate-/high-dose or potent ICSs, incorrect inhaler technique, failure to protect skin or eyes when using ICS by nebuliser or 
spacer with face mask
ICSs = inhaled corticosteroids; OCSs = oral corticosteroids.
*Adapted from Global Initiative for Asthma.[1]
Box 2. Confirmation of variable airflow limitation and grade of recommendation 
Pulmonary function test Grade
Reduced FEV1/FVC (normal >0.9) when FEV1 is low A
Positive bronchodilator reversibility test with an increase in FEV1 of >12% predicted A
Positive exercise challenge test with a fall in FEV1 of >12% predicted or PEF >15%, target heart rate (0.8 × 220 - age in years) and  
noting that target heart rate can be reached earlier in children
A
PEF variability 2 weeks twice a day, with an average daily diurnal PEF variability of >13% A
Excessive variation of pulmonary function between outpatient visits with variability of FEV1 >12% or PEF >15% (using the same  
peak flow meter during each visit) with or without respiratory tract infections
A
FEV1 = forced expiratory volume in 1 second; PEF = peak expiratory flow.  
Box 3. Recommendations to achieve asthma control and level of evidence
Recommendations
Level of 
evidence
Once an asthmatic is on controller therapy, regular assessment of control is critical. Of equal importance is regular 
assessment of future risk (exacerbations and side-effects)
A
Control must be formally measured at every visit and not fewer than 6-monthly B
Formal tools for assessing control include symptom assessments, scores (such as the cACT and ACQ) and spirometry B
For uncontrolled asthma in children >5 years old using a low-dose ICS, doubling the dose of ICS is as beneficial as adding 
a LABA
A
Where ICSs cause local or systemic side-effects or there is a risk of such side-effects, LABA addition is preferred for poorly 
controlled asthma in children >5 years of age 
C
In more severe asthma, before the dose of ICS is increased or a new drug is added, it is critical to assess the reasons for 
poor control thoroughly, including reconsidering the diagnosis, educating patients and treating comorbidities
B
LABA use has not been well studied in preschool children and efficacy and safety are not established. LABAs should not be 
used in these children
C
LTRA use has been poorly studied in preschool children. LTRAs’ relatively clean safety profile makes them preferred add-
on options for poorly controlled preschool asthmatics
B
cACT = childhood Asthma Control Test; ACQ = Asthma Control Questionnaire; ICSs = inhaled corticosteroids; LTRAs = leukotriene receptor antagonists; LABAs = long-acting beta agonists.
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Predictors of asthma in childhood
Factors that independently predict asthma in late childhood are male 
sex, post-term delivery, medium or low parental education, family 
history of asthma and/or other atopic diseases, frequency of wheeze 
and wheezing dyspnoea (not associated with a cold).[5] 
Asthma control
Asthma control is the extent to which asthma symptoms can be 
observed in a patient or have been reduced or eliminated by treatment.[1] 
The recent Global Initiative for Asthma (GINA) guidelines suggest 
that the monitoring of asthma control is essential in all asthmatics.[1] 
Assessment of control should evaluate symptoms (over the past week 
and month) and quality of life. The risk of future exacerbations (as 
measured by spirometry and, possibly, exhaled nitric oxide) and 
medication side-effects (as a result of steroid use and, particularly, 
growth in children) must be assessed regularly. Optimal formal tools 
for assessing control offer the best insight into asthma control.[13] No 
test is a gold standard and all tests must be used in conjunction to 
assess control (evidence level B).[14] Every practitioner and all children 
>6 years of age should have access to a peak flow meter to assess 
changes in lung function.
Asthma control is significantly more likely in patients or parents/
caregivers who are educated (know their disease), are regularly taught 
to use the inhaler device, have a written action plan and educational 
material (www.asthmasa.co.za) and are encouraged to use controller 
medication regularly (level I evidence). If control is suboptimal, 
determine the reasons and educate the patient. A small number of 
patients need adjustment of their treatment (Box 3).
The child should demonstrate clinical improvement during the 2 - 
3 months of controller treatment, with worsening of symptoms after 
treatment cessation (Fig. 1). Thereafter, assessment of asthma control 
and future risk can be determined at each visit (Table 4).
Conclusion
Asthma in young children should only be diagnosed when all other 
causes of wheezing have been considered and excluded, more so 
in younger children. A therapeutic trial should be performed in 
uncertain cases, with follow-up and withdrawal of therapy to confirm 
or exclude the diagnosis of asthma. Asthma control should be 
assessed at each visit to guide therapeutic decisions.
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Appendix A. The SA Childhood 
Asthma Working Group (SACAWG)
Epidemiology: H Zar (leader), Western Cape; C Gray, Western Cape.
Diagnosis of asthma: R Masekela (leader), KwaZulu-Natal; 
S M Risenga, Limpopo; O P Kitchin, Gauteng; P Goussard, 
Western Cape.
Assessment of asthma control: R J Green (leader), Gauteng; D White, 
 Gauteng; G Davis, Gauteng.
Pharmacotherapy: F E Kritzinger (leader), Western Cape; A Jeevan -
a thrum, Gauteng; P de Waal, Free State; S Kling, Western Cape; 
A Vanker, Western Cape; T C Gray, Western Cape; J Morrison, 
Western Cape; A Puterman, Western Cape; E Zollner, Western 
Cape; D Rhode, Western Cape.
Pharmacotherapy – other therapies: A I Manjra (leader), KwaZulu-
Natal; P M Jeena, KwaZulu-Natal; V Naidoo, KwaZulu-Natal; 
M Annamalai, KwaZulu-Natal; A van Niekerk, Gauteng.
Self-management plans: M Levin (leader), Western Cape; 
S Ema nuel, Western Cape; D Hawarden, Western Cape; H Katz, 
Gauteng.
Appendix B. Level of evidence 
IA Evidence from meta-analysis and randomised controlled trials
IB Evidence from at least one randomised controlled trial
IIA Evidence from at least one controlled trial without randomisation
IIB Evidence from at least one or other quasi-experimental study
III  Evidence from non-experimental descriptive studies, such as 
comparative studies, correlation studies and case-controlled studies
IV  Evidence from expert committee reports, opinions or clinical 
experience of respected authorities
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Appendix B. Grades of Recommendation Assessment, Development and Evaluation (GRADE) 
Level of recommendation Quality of evidence Definition
A High High-quality research very unlikely to change our confidence in the estimate effect based 
on level I evidence
B Moderate Moderate-quality evidence, where future research is likely to have an important impact 
on our confidence in the estimate effect. Based on level II evidence or extrapolated from 
recommendations from level I evidence
C Low Low-quality evidence, where future research is likely to have an important impact on our 
confidence in the estimate effect. Based on level III evidence or recommendations from 
level I and II evidence
D Very low Very-low-quality evidence, where the estimate effect is uncertain. Based on level IV 
evidence or recommendations from level I, II and III evidence
Appendix C. Lung function testing in children >5 years of age and level of evidence[12]
Lung function test Advantages Disadvantages Level of evidence
Peak flow Cheap 
Easy-to-teach technique
Pre-diagnosis and  disease monitoring for older patients
Not reliable in young children II
Spirometry Computer incentive-based devices can obtain reliable 
tests in 2 - 6-year-olds
Available at most centres
Assess reversibility to bronchodilator
FEV1 0.5 and FEV1 0.75 may be more 
reliable in preschoolers 
FEV1 0.5 an FEV1 0.75 (not validated for 
clinical application)
Needs active co-operation and breath 
control 
I
Bronchial responsiveness Successful in preschoolers and differentiates between 
chronic asthma and chronic coughing
Facilitates diagnosis of asthma
Currently no recommendations for  
cold air challenge testing
II
